A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Eligibility Criteria

• * Age ≥ 18 years old at the time of enrolment.
• * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.
• * Expected life expectancy ≥ 3 months.
• * Newly diagnosed HR-MDS, according to the 2016 World Health Organization (WHO) classification with the presence of \< 20% blasts in bone marrow or peripheral blood; Overall IPSS-R score ≥ 3.5.
• * Ability to undergo the study-required bone marrow sample collection procedures.
• * Suitable venous access for the study-required blood sampling (i.e., including PK and immunogenicity).
• * Female patients of childbearing age must have negative serum pregnancy test results before randomization or per region-specific guidance documented in the informed consent and a negative urine pregnancy test on the day of first dose prior to dosing.
• * Female patients of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of contraception from the beginning of screening until 180 days after the last dose of the study treatment.
• * Unsterilized male patients having sex with a female partner of childbearing potential must agree to use an effective method of contraception from the beginning of screening until 180 days after the last dose of study treatment.
• * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN).
• * Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents.
• * Concurrently participating in another interventional clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
• * Patients who previously diagnosed with another malignancy and have any evidence of residual disease.
• * Known allergy to any component of any study drug; known history of severe hypersensitivity to other monoclonal antibodies.
• * Patients with any psychiatric or social factor which the investigator deems may interfere with the patient's ability to comply with the requirements of the study.
• * Patients with current hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy.
• * Patients with known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders.
• * Patients who are breastfeeding or plans to breastfeed during the study.
• * Other conditions where the investigator considers the patient inappropriate for enrollment.